Eli Lilly (LLY) that it will invest $3B in a new manufacturing facility in Katwijk, Netherlands, situated in the Leiden Bio Science Park.
This facility will be responsible for producing orforglipron, Lilly’s first oral GLP-1 receptor agonist aimed at treating obesity, among other drugs. The company plans to submit this medication for approval to global regulatory bodies by the end of the year.
The project is expected to create 500 high-paying jobs in the South Holland region. Additionally, around 1,500 jobs will be generated during the construction phase, which is set to commence next year, pending the necessary government permits and local approvals.
Lilly also announced plans to expand its existing manufacturing operations in Puerto Rico and establish new sites in Texas and Virginia, with two more locations in the U.S. to be disclosed in the coming months.